This study was designed to determine the analgesic efficacy and tolerability of parecoxib, cyclooxygenase-2 inhibitor, by comparing it with Icetorolac and placebo in postoperative pain control after open prostatectomy. Sixty patients undergoing open prostatectonty were evaluated. The patients were divided into three equal groups. Group I received IV parecoxib 40mg, group II received IV ketorolac 30mg, and group III received IV placebo postoperatively every 6 hours for 24 hours. PostoPeratively, all patients received intravenous morphine using patient controlled analgesia pump (PCA). The outcome measures included pain scores and morphine consumption in the first 24 hours postoperatively. Bleeding time was determined immediately postoperatively and after 24 hours of the study drug administration. Pare coxib sodium 40mg reduced the total amount of morphine required over 24-hours by 36% also ketorolac 30mg reduced morphine consumption by 33.5%, compared with placebo (P<0.001). Patients who received 40mg parecoxib sodium or 30mg ketorolac experienced significantly greater maximum pain relief compared with those in the placebo group (P <0.05). Patients who received 40mg parecoxib or 30 mg ketorolac discontinued PCA with morphine earlier than patients received placebo and had significantly higher global evaluation ratings |
